Core Insights - Kenvue Inc. (KVUE) is valued at a market cap of $33.5 billion and focuses on consumer health products, but has underperformed the broader market over the past year [1] - The company's shares have declined 18.4% in the last 52 weeks, while the S&P 500 Index has gained 16.1% [1] - On November 3, shares rose 12.3% following an announcement of an acquisition agreement by Kimberly-Clark Corporation (KMB), valuing Kenvue at approximately $48.7 billion [3] Performance Metrics - Year-to-date, KVUE's stock is up 1.5%, compared to the S&P 500's 1.9% return [1] - KVUE has also underperformed the State Street Consumer Staples Select Sector SPDR ETF (XLP), which rose 3.9% over the past 52 weeks [2] - Analysts expect KVUE's EPS to decline 9.7% year-over-year to $1.03 for the current fiscal year [4] Analyst Ratings - The consensus rating among 12 analysts covering KVUE is a "Hold," with two "Strong Buy" and ten "Hold" ratings [4] - The mean price target of $19 represents an 8.6% premium from current price levels, while the highest price target of $23 suggests a 31.4% potential upside [6] - The overall rating has shifted to "Moderate Buy" from a more bullish stance three months ago, with five analysts suggesting a "Strong Buy" [5]